<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413686</url>
  </required_header>
  <id_info>
    <org_study_id>D1040C00002</org_study_id>
    <nct_id>NCT00413686</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety,
      tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762
      administered as a single intravenous unit and in combination with gemcitabine. The study is
      sponsored by AstraZeneca.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of AZD7762 alone and in combination with Gemcitabine</measure>
    <time_frame>Assessed after each course of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the single-dose (after the first single-agent dose) and combination-dose (afer the 2nd combination dose) pharmacokinetics (PK) of AZD7762.</measure>
    <time_frame>Assessed after each course of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7762 monotherapy followed by AZD7762 + gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7762</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>weekly intravenous infusion</description>
    <arm_group_label>1</arm_group_label>
    <other_name>GemzarÂ®</other_name>
    <other_name>Gemcitabine HCL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed malignancy that is metastatic or
             unresectable and for which standard curative or palliative measures do not exist or
             are no longer effective

          -  ECOG performance status of 0 or 1

          -  Patient and tumor type must be suitable for treatment with weekly standard
             gemcitabine.

        Exclusion Criteria:

          -  Inadequate bone marrow reserve, inadequate liver function or impaired renal function

          -  Any troponin elevation (above normal range)

          -  Stage II, III, or IV cardiac status, according to New York Heart Association (NYHA)
             classification; recent history (ie, within 6 months) of coronary artery disease or
             arteriosclerotic cardiovascular disease (angina, myocardial infarction [MI])

          -  Any prior anthracycline treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Langmuir, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <last_update_submitted>December 3, 2010</last_update_submitted>
  <last_update_submitted_qc>December 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Mixed solid tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

